



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER		% Change		
	2021	2020	Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
<u>OTC</u>					
US	\$ 675	627	7.7%	7.7%	-
Intl	633	522	21.2%	10.4%	10.8%
WW	1,307	1,149	13.8%	8.9%	4.9%
<u>SKIN HEALTH / BEAUTY</u>					
US	659	536	23.0%	23.0%	-
Intl	511	471	8.4%	1.4%	7.0%
WW	1,170	1,007	16.2%	12.9%	3.3%
<u>ORAL CARE</u>					
US	165	170	-3.1%	-3.1%	-
Intl	260	227	14.6%	6.7%	7.9%
WW	426	397	7.0%	2.5%	4.5%
<u>BABY CARE</u>					
US	97	96	0.8%	0.8%	-
Intl	290	260	11.5%	6.6%	4.9%
WW	387	356	8.6%	5.0%	3.6%
<u>WOMEN'S HEALTH</u>					
US	3	3	-3.1%	-3.1%	-
Intl	227	199	14.2%	9.2%	5.0%
WW	230	202	13.9%	9.0%	4.9%
<u>WOUND CARE / OTHER</u>					
US	153	126	20.9%	20.9%	-
Intl	64	59	7.3%	-2.8%	10.1%
WW	216	185	16.6%	13.4%	3.2%
TOTAL CONSUMER HEALTH					
US	1,751	1,557	12.4%	12.4%	-
Intl	1,984	1,739	14.1%	6.3%	7.8%
WW	\$ 3,735	3,296	13.3%	9.2%	4.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SIX MONTHS		% Change		
	2021	2020	Reported	Operational ⁽¹⁾	Currency
	\$ 1,274	1,316	-3.2%	-3.2%	-
	1,208	1,181	2.3%	-4.7%	7.0%
	2,482	2,497	-0.6%	-3.9%	3.3%
	1,293	1,195	8.2%	8.2%	-
	1,040	929	12.0%	6.8%	5.2%
	2,333	2,124	9.8%	7.6%	2.2%
	328	346	-5.2%	-5.2%	-
	514	446	15.3%	10.2%	5.1%
	843	792	6.3%	3.5%	2.8%
	193	188	2.4%	2.4%	-
	583	529	10.2%	9.0%	1.2%
	776	717	8.1%	7.3%	0.8%
	6	7	-16.0%	-16.0%	-
	446	427	4.5%	3.1%	1.4%
	452	434	4.2%	2.8%	1.4%
	268	245	9.3%	9.3%	-
	125	111	12.1%	5.2%	6.9%
	393	356	10.2%	8.0%	2.2%
	3,362	3,297	2.0%	2.0%	-
	3,916	3,624	8.1%	3.3%	4.8%
	\$ 7,278	6,921	5.2%	2.7%	2.5%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT ^(2,3)	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2021	2020	Reported	% Change Operational ⁽¹⁾	Currency	2021	2020	Reported	% Change Operational ⁽¹⁾	Currency
IMMUNOLOGY										
US	\$ 2,748	2,362	16.4%	16.4%	-	\$ 5,161	4,772	8.2%	8.2%	-
Intl	1,483	1,161	27.7%	18.2%	9.5%	2,984	2,389	24.9%	17.0%	7.9%
WW	4,231	3,523	20.1%	17.0%	3.1%	8,145	7,161	13.7%	11.1%	2.6%
REMICADE										
US	540	593	-9.1%	-9.1%	-	1,029	1,218	-15.6%	-15.6%	-
US Exports ⁽⁴⁾	93	133	-30.0%	-30.0%	-	150	243	-38.2%	-38.2%	-
Intl	255	208	22.4%	11.1%	11.3%	487	464	4.9%	-1.7%	6.6%
WW	888	935	-5.1%	-7.6%	2.5%	1,665	1,925	-13.5%	-15.1%	1.6%
SIMPONI / SIMPONI ARIA										
US	290	256	12.8%	12.8%	-	545	528	3.2%	3.2%	-
Intl	294	289	1.7%	-3.8%	5.5%	601	547	9.8%	4.5%	5.3%
WW	584	546	6.9%	4.0%	2.9%	1,146	1,075	6.6%	3.8%	2.8%
STELARA										
US	1,496	1,138	31.4%	31.4%	-	2,827	2,355	20.0%	20.0%	-
Intl	778	558	39.2%	28.6%	10.6%	1,595	1,161	37.3%	28.1%	9.2%
WW	2,274	1,697	34.0%	30.5%	3.5%	4,422	3,516	25.8%	22.7%	3.1%
TREMFYA										
US	325	241	35.0%	35.0%	-	599	428	40.0%	40.0%	-
Intl	155	101	52.3%	41.1%	11.2%	298	210	41.8%	31.8%	10.0%
WW	479	342	40.2%	36.8%	3.4%	897	638	40.6%	37.3%	3.3%
OTHER IMMUNOLOGY										
US	5	-	*	*	-	12	-	*	*	-
Intl	1	3	-61.3%	-67.9%	6.6%	3	6	-51.2%	-53.9%	2.7%
WW	7	3	*	*	*	15	6	*	*	*
INFECTIOUS DISEASES										
US	444	416	6.8%	6.8%	-	956	852	12.2%	12.2%	-
Intl	585	463	26.3%	18.2%	8.1%	1,079	946	14.1%	7.8%	6.3%
WW	1,028	878	17.1%	12.8%	4.3%	2,035	1,798	13.2%	9.9%	3.3%
COVID-19 VACCINE										
US	51	-	*	*	-	151	-	*	*	-
Intl	113	-	*	*	-	113	-	*	*	-
WW	164	-	*	*	-	264	-	*	*	-
EDURANT / rilpivirine										
US	9	10	-9.3%	-9.3%	-	19	22	-10.9%	-10.9%	-
Intl	253	246	2.8%	-4.0%	6.8%	486	458	6.0%	-1.7%	7.7%
WW	262	256	2.3%	-4.2%	6.5%	505	480	5.2%	-2.1%	7.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA										
US	368	379	-3.2%	-3.2%	-	748	775	-3.5%	-3.5%	-
Intl	137	130	5.5%	-5.9%	11.4%	303	314	-3.5%	-8.5%	5.0%
WW	505	510	-1.0%	-3.9%	2.9%	1,051	1,089	-3.5%	-5.0%	1.5%
OTHER INFECTIOUS DISEASES										
US	16	25	-36.2%	-36.2%	-	37	54	-31.3%	-31.3%	-
Intl	81	87	-6.2%	-13.4%	7.2%	177	174	1.8%	-3.0%	4.8%
WW	98	113	-13.0%	-18.5%	5.5%	215	229	-6.1%	-9.7%	3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER

NEUROSCIENCE

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	842	778	8.0%	8.0%	-
Intl	967	809	19.6%	13.1%	6.5%
WW	1,808	1,587	13.9%	10.6%	3.3%
<u>CONCERTA / Methylphenidate</u>					
US	35	55	-36.0%	-36.0%	-
Intl	127	94	33.7%	25.6%	8.1%
WW	161	149	8.1%	3.0%	5.1%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	645	576	11.9%	11.9%	-
Intl	380	303	25.1%	15.9%	9.2%
WW	1,024	879	16.4%	13.3%	3.1%
<u>RISPERDAL CONSTA</u>					
US	72	74	-3.0%	-3.0%	-
Intl	84	79	6.4%	0.2%	6.2%
WW	155	153	1.9%	-1.3%	3.2%
<u>OTHER NEUROSCIENCE</u>					
US	91	75	20.9%	20.9%	-
Intl	377	331	13.8%	10.0%	3.8%
WW	468	406	15.1%	12.0%	3.1%
<u>ONCOLOGY</u>					
US	1,462	1,181	23.7%	23.7%	-
Intl	2,073	1,609	28.8%	19.8%	9.0%
WW	3,535	2,791	26.7%	21.5%	5.2%
<u>DARZALEX</u>					
US	770	492	56.7%	56.7%	-
Intl	663	409	62.1%	50.3%	11.8%
WW	1,433	901	59.2%	53.8%	5.4%
<u>ERLEADA</u>					
US	193	136	41.5%	41.5%	-
Intl	109	33	*	*	*
WW	302	170	77.6%	73.7%	3.9%
<u>IMBRUVICA</u>					
US	454	447	1.7%	1.7%	-
Intl	662	502	31.9%	22.1%	9.8%
WW	1,116	949	17.7%	12.5%	5.2%
<u>ZYTIGA / abiraterone acetate</u>					
US	21	87	-75.3%	-75.3%	-
Intl	542	480	12.8%	5.4%	7.4%
WW	563	568	-0.8%	-7.1%	6.3%
<u>OTHER ONCOLOGY</u>					
US	23	20	18.8%	18.8%	-
Intl	97	185	-47.2%	-49.6%	2.4%
WW	120	204	-40.9%	-43.0%	2.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	1,613	1,526	5.6%	5.6%	-
Intl	1,916	1,719	11.5%	6.3%	5.2%
WW	3,529	3,245	8.7%	6.0%	2.7%
US	82	107	-23.1%	-23.1%	-
Intl	250	212	17.5%	11.1%	6.4%
WW	332	320	3.9%	-0.3%	4.2%
US	1,234	1,120	10.2%	10.2%	-
Intl	756	642	17.7%	9.9%	7.8%
WW	1,989	1,762	12.9%	10.1%	2.8%
US	139	150	-7.5%	-7.5%	-
Intl	173	173	0.4%	-4.6%	5.0%
WW	312	323	-3.3%	-6.0%	2.7%
US	158	150	5.6%	5.6%	-
Intl	738	691	6.7%	4.3%	2.4%
WW	896	841	6.5%	4.5%	2.0%
US	2,839	2,356	20.5%	20.5%	-
Intl	4,266	3,448	23.7%	16.2%	7.5%
WW	7,105	5,804	22.4%	17.9%	4.5%
US	1,461	955	53.1%	53.1%	-
Intl	1,337	883	51.4%	42.3%	9.1%
WW	2,798	1,838	52.2%	47.9%	4.3%
US	364	255	42.7%	42.7%	-
Intl	199	57	*	*	*
WW	563	313	80.0%	76.4%	3.6%
US	898	879	2.2%	2.2%	-
Intl	1,342	1,101	21.9%	14.2%	7.7%
WW	2,241	1,980	13.2%	8.9%	4.3%
US	71	226	-68.5%	-68.5%	-
Intl	1,130	1,032	9.5%	2.5%	7.0%
WW	1,201	1,258	-4.5%	-10.3%	5.8%
US	44	42	6.3%	6.3%	-
Intl	258	375	-31.0%	-34.3%	3.3%
WW	302	416	-27.3%	-30.2%	2.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SECOND QUARTER

PULMONARY HYPERTENSION

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	595	545	9.0%	9.0%	-
Intl	275	243	13.5%	7.9%	5.6%
WW	<u>870</u>	<u>789</u>	10.4%	8.7%	1.7%
<u>OPSUMIT</u>					
US	290	256	13.6%	13.6%	-
Intl	172	150	14.9%	9.0%	5.9%
WW	<u>463</u>	<u>406</u>	14.1%	11.9%	2.2%
<u>UPTRAVI</u>					
US	268	254	6.0%	6.0%	-
Intl	45	28	54.9%	42.9%	12.0%
WW	<u>313</u>	<u>282</u>	11.0%	9.8%	1.2%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	36	37	-2.4%	-2.4%	-
Intl	59	64	-8.2%	-10.3%	2.1%
WW	<u>95</u>	<u>101</u>	-6.1%	-7.5%	1.4%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	780	837	-6.9%	-6.9%	-
Intl	346	347	-0.3%	-8.4%	8.1%
WW	<u>1,126</u>	<u>1,184</u>	-5.0%	-7.3%	2.3%
<u>XARELTO</u>					
US	569	559	1.8%	1.8%	-
Intl	-	-	-	-	-
WW	<u>569</u>	<u>559</u>	1.8%	1.8%	-
<u>INVOKANA / INVOKAMET</u>					
US	96	132	-27.0%	-27.0%	-
Intl	64	47	33.8%	22.1%	11.7%
WW	<u>160</u>	<u>179</u>	-10.9%	-14.0%	3.1%
<u>PROCRIT / EPREX</u>					
US	59	70	-16.3%	-16.3%	-
Intl	69	66	3.7%	-4.5%	8.2%
WW	<u>127</u>	<u>136</u>	-6.6%	-10.6%	4.0%
<u>OTHER</u>					
US	57	78	-26.7%	-26.7%	-
Intl	214	234	-8.4%	-15.7%	7.3%
WW	<u>271</u>	<u>312</u>	-13.0%	-18.4%	5.4%
<u>TOTAL PHARMACEUTICAL</u>					
US	6,869	6,120	12.2%	12.2%	-
Intl	5,730	4,632	23.7%	15.4%	8.3%
WW	<u>\$ 12,599</u>	<u>10,752</u>	17.2%	13.6%	3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

SIX MONTHS

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
	1,168	1,031	13.2%	13.2%	-
	563	503	12.1%	6.7%	5.4%
	<u>1,731</u>	<u>1,534</u>	12.9%	11.1%	1.8%
	562	485	15.9%	15.9%	-
	351	310	13.1%	7.6%	5.5%
	<u>913</u>	<u>795</u>	14.8%	12.7%	2.1%
	527	466	13.3%	13.3%	-
	91	66	36.8%	27.4%	9.4%
	<u>618</u>	<u>532</u>	16.2%	15.0%	1.2%
	78	81	-3.0%	-3.0%	-
	122	126	-3.5%	-6.3%	2.8%
	<u>200</u>	<u>207</u>	-3.3%	-5.0%	1.7%
	1,579	1,643	-3.9%	-3.9%	-
	674	701	-3.8%	-9.9%	6.1%
	<u>2,253</u>	<u>2,344</u>	-3.9%	-5.7%	1.8%
	1,158	1,086	6.6%	6.6%	-
	-	-	-	-	-
	<u>1,158</u>	<u>1,086</u>	6.6%	6.6%	-
	183	249	-26.6%	-26.6%	-
	127	105	20.3%	12.2%	8.1%
	<u>310</u>	<u>354</u>	-12.6%	-15.0%	2.4%
	121	146	-17.3%	-17.3%	-
	133	145	-8.2%	-14.1%	5.9%
	<u>254</u>	<u>291</u>	-12.8%	-15.7%	2.9%
	117	163	-27.8%	-27.8%	-
	415	451	-8.1%	-13.7%	5.6%
	<u>532</u>	<u>614</u>	-13.3%	-17.4%	4.1%
	13,315	12,181	9.3%	9.3%	-
	11,483	9,705	18.3%	11.4%	6.9%
	<u>\$ 24,798</u>	<u>21,886</u>	13.3%	10.3%	3.0%

See footnotes at end of schedule

MEDICAL DEVICES SEGMENT ⁽²⁾

INTERVENTIONAL SOLUTIONS

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	\$ 475	255	86.5%	86.5%	-	-	-
Intl	572	335	70.5%	59.8%	10.7%	10.7%	10.7%
WW	1,046	590	77.4%	71.3%	6.1%	6.1%	6.1%

ORTHOPAEDICS

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	1,323	869	52.3%	52.3%	-	-	-
Intl	904	583	55.1%	43.2%	11.9%	11.9%	11.9%
WW	2,227	1,451	53.4%	48.6%	4.8%	4.8%	4.8%

HIPS

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	234	137	70.5%	70.5%	-	-	-
Intl	159	88	78.6%	64.3%	14.3%	14.3%	14.3%
WW	392	226	73.7%	68.1%	5.6%	5.6%	5.6%

KNEES

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	210	108	94.3%	94.3%	-	-	-
Intl	140	66	*	95.1%	16.8%	16.8%	16.8%
WW	350	174	*	94.6%	6.4%	6.4%	6.4%

TRAUMA

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	447	354	26.0%	26.0%	-	-	-
Intl	263	198	32.7%	22.7%	10.0%	10.0%	10.0%
WW	710	553	28.4%	24.8%	3.6%	3.6%	3.6%

SPINE, SPORTS & OTHER

	2021		2020		% Change		Currency
	2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
US	433	270	60.6%	60.6%	-	-	-
Intl	343	230	49.0%	37.9%	11.1%	11.1%	11.1%
WW	776	499	55.3%	50.2%	5.1%	5.1%	5.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

		2021		2020		% Change		Currency
		2021	2020	Reported	Operational ⁽¹⁾	Reported	Operational ⁽¹⁾	
		909	620	46.7%	46.7%	-	-	-
		1,086	697	55.7%	46.4%	9.3%	9.3%	9.3%
		1,995	1,317	51.5%	46.5%	5.0%	5.0%	5.0%
		2,572	2,119	21.4%	21.4%	-	-	-
		1,768	1,371	29.0%	20.2%	8.8%	8.8%	8.8%
		4,340	3,489	24.4%	20.9%	3.5%	3.5%	3.5%
		444	343	29.6%	29.6%	-	-	-
		305	220	38.3%	28.6%	9.7%	9.7%	9.7%
		749	563	33.0%	29.2%	3.8%	3.8%	3.8%
		395	322	22.7%	22.7%	-	-	-
		272	196	39.2%	29.5%	9.7%	9.7%	9.7%
		667	517	28.9%	25.2%	3.7%	3.7%	3.7%
		897	761	17.8%	17.8%	-	-	-
		545	445	22.5%	14.4%	8.1%	8.1%	8.1%
		1,443	1,207	19.6%	16.5%	3.1%	3.1%	3.1%
		836	693	20.7%	20.7%	-	-	-
		646	510	26.7%	18.0%	8.7%	8.7%	8.7%
		1,482	1,202	23.2%	19.6%	3.6%	3.6%	3.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SECOND QUARTER					
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
SURGERY					
US	1,035	490	*	*	-
Intl	1,487	1,060	40.2%	30.6%	9.6%
WW	2,522	1,551	62.6%	56.0%	6.6%
ADVANCED					
US	459	277	65.4%	65.4%	-
Intl	708	498	42.2%	32.5%	9.7%
WW	1,168	775	50.5%	44.3%	6.2%
GENERAL					
US	576	213	*	*	-
Intl	779	562	38.5%	28.9%	9.6%
WW	1,354	775	74.7%	67.8%	6.9%
VISION					
US	467	248	88.3%	88.3%	-
Intl	716	447	60.0%	53.7%	6.3%
WW	1,183	695	70.1%	66.0%	4.1%
CONTACT LENSES / OTHER					
US	352	203	73.3%	73.3%	-
Intl	517	352	47.0%	41.9%	5.1%
WW	868	554	56.7%	53.4%	3.3%
SURGICAL					
US	115	45	*	*	-
Intl	199	96	*	97.1%	10.6%
WW	314	141	*	*	*
TOTAL MEDICAL DEVICES					
US	3,299	1,862	77.2%	77.2%	-
Intl	3,679	2,426	51.6%	41.9%	9.7%
WW	\$ 6,978	4,288	62.7%	57.2%	5.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
SIX MONTHS					
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
	1,933	1,334	44.9%	44.9%	-
	2,961	2,317	27.8%	20.4%	7.4%
	4,894	3,651	34.0%	29.3%	4.7%
	864	658	31.3%	31.3%	-
	1,421	1,065	33.4%	25.6%	7.8%
	2,286	1,723	32.6%	27.8%	4.8%
	1,069	676	58.1%	58.1%	-
	1,540	1,252	23.0%	15.9%	7.1%
	2,608	1,928	35.3%	30.7%	4.6%
	939	687	36.6%	36.6%	-
	1,389	1,075	29.2%	24.6%	4.6%
	2,328	1,762	32.1%	29.3%	2.8%
	723	549	31.6%	31.6%	-
	1,003	819	22.5%	18.5%	4.0%
	1,725	1,368	26.1%	23.7%	2.4%
	216	138	56.3%	56.3%	-
	386	256	50.9%	44.4%	6.5%
	602	394	52.8%	48.6%	4.2%
	6,353	4,760	33.5%	33.5%	-
	7,204	5,460	31.9%	24.5%	7.4%
	\$ 13,557	10,220	32.7%	28.7%	4.0%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales